Article
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2014
Luchman H Artee, Stechishin Owen D M, Nguyen Stephanie A, Lun Xueqing Q, Cairncross J Gregory, Weiss Samuel
Abstract excerpt
PURPOSE: The EGFR and PI3K/mTORC1/2 pathways are frequently altered in glioblastoma (GBM), but pharmacologic targeting of EGFR and PI3K signaling has failed to demonstrate efficacy in clinical trials. Lack of relevant models has rendered it difficult to assess whether targeting these pathways mig...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.